PharmExec articleshttps://www.pharmexec.com/newsPharmExec articles© 2026 MJH Life Sciences™ and PharmExec. All rights reserved.Sun, 10 May 2026 17:08:29 +00005en-us14447https://www.pharmexec.com/newshttps://www.pharmexec.com/logo.webphttps://www.pharmexec.com/view/president-trump-planning-fire-fda-commissioner-marty-makary-reporthttps://www.pharmexec.com/view/president-trump-planning-fire-fda-commissioner-marty-makary-report<![CDATA[President Trump is reportedly planning to dismiss FDA Commissioner Marty Makary, adding further leadership uncertainty across U.S. health agencies.]]>Fri, 08 May 2026 19:04:28 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/daily-fda-extends-review-leqembi-sblahttps://www.pharmexec.com/view/daily-fda-extends-review-leqembi-sbla<![CDATA[In today’s Pharmaceutical Executive Daily, the FDA extends its priority review of a subcutaneous formulation of Leqembi, industry analysts examine how upcoming GLP-1 patent expirations could reshape the drug delivery device market, and experts discuss the key forces driving renewed growth in radiopharmaceuticals.]]>Fri, 08 May 2026 17:51:49 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/fda-extends-priority-review-leqembi-iqlik-subcutaneous-injectionhttps://www.pharmexec.com/view/fda-extends-priority-review-leqembi-iqlik-subcutaneous-injection<![CDATA[FDA extended its review of Leqembi’s once-weekly subcutaneous starting dose for early Alzheimer’s disease by three months after requesting additional information from Eisai and Biogen.]]>Fri, 08 May 2026 14:04:51 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/glp1-patent-expiry-rise-generics-transforming-drug-delivery-device-landscape-procurement-strategyhttps://www.pharmexec.com/view/glp1-patent-expiry-rise-generics-transforming-drug-delivery-device-landscape-procurement-strategy<![CDATA[An expected surge in generic GLP-1s is anticipated to reshape not only pharmaceutical pricing and access but also the global MedTech ecosystem supporting drug delivery.]]>Fri, 08 May 2026 10:00:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/factors-contributing-growth-radiopharmaceuticals-andrea-zobel-marco-hogenboomhttps://www.pharmexec.com/view/factors-contributing-growth-radiopharmaceuticals-andrea-zobel-marco-hogenboom<![CDATA[Radiopharmaceutical logistics is fundamentally different from traditional pharmaceutical supply chains.]]>Fri, 08 May 2026 10:00:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/daily-angelini-pharma-acquires-catalyst-pharmaceuticals-4-billion-agreementhttps://www.pharmexec.com/view/daily-angelini-pharma-acquires-catalyst-pharmaceuticals-4-billion-agreement<![CDATA[In today's Pharmaceutical Executive Daily, Angelini Pharma announces a $4.1 billion agreement to acquire Catalyst Pharmaceuticals, Incyte presents 24-week results from the Phase III TRuE-AD4 trial of Opzelura, and Pharmaceutical Executive speaks with Charlie Lyon of the API Innovation Center on what the conversation about bringing pharmaceutical manufacturing back to the United States is still missing.]]>Thu, 07 May 2026 19:25:55 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/incyte-announces-week-24-results-true-ad4-phase-iii-trial-opzelurahttps://www.pharmexec.com/view/incyte-announces-week-24-results-true-ad4-phase-iii-trial-opzelura<![CDATA[Incyte reports sustained 24-week efficacy and consistent safety data for Opzelura cream in moderate atopic dermatitis, supporting interest in nonsteroidal topical therapies for long-term disease control.]]>Thu, 07 May 2026 13:54:27 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/angelini-enters-4-billion-agreement-acquire-catalysthttps://www.pharmexec.com/view/angelini-enters-4-billion-agreement-acquire-catalyst<![CDATA[Angelini Pharma acquires Catalyst Pharmaceuticals in a $4.1 billion deal, expanding into the U.S. rare disease market and adding a portfolio of approved neuromuscular and neurological therapies.]]>Thu, 07 May 2026 13:26:02 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/strengthening-generic-drugs-supply-chainhttps://www.pharmexec.com/view/strengthening-generic-drugs-supply-chain<![CDATA[Natalie de Graaf, from the API Innovation Center, discusses a recent whitepaper detailing areas where the generic drugs pipeline is under stress.]]>Thu, 07 May 2026 10:00:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/what-elements-conversation-about-bringing-manufacturing-home-missinghttps://www.pharmexec.com/view/what-elements-conversation-about-bringing-manufacturing-home-missing<![CDATA[Charlie Lyon, VP of manufacturing, procurement, and logistics at the API Innovation Center, discusses the complicated web of global manufacturing.]]>Thu, 07 May 2026 10:00:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/winning-in-ai-overviews-protecting-brand-accuracy-in-ai-generated-answershttps://www.pharmexec.com/view/winning-in-ai-overviews-protecting-brand-accuracy-in-ai-generated-answers<![CDATA[Webinar Date/Time: Thu, May 28, 2026 11:00 AM EDT]]>Thu, 07 May 2026 04:00:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/daily-zentalis-doses-first-patient-azenosertib-phase-iii-trialhttps://www.pharmexec.com/view/daily-zentalis-doses-first-patient-azenosertib-phase-iii-trial<![CDATA[In today's Pharmaceutical Executive Daily, Bayer agrees to acquire Perfuse Therapeutics for up to $2.45 billion and Madrigal obtains an exclusive global license for a precision siRNA therapy targeting a key genetic driver of MASH, Zentalis Pharmaceuticals announces the first patient dosed in a Phase III trial and Brooke Ervin argues that translating real-world evidence into commercial and clinical impact in urology requires more than access to data.]]>Wed, 06 May 2026 18:15:43 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/first-patient-dosed-azenosertib-aspenova-phase-iii-trial-ovarian-cancerhttps://www.pharmexec.com/view/first-patient-dosed-azenosertib-aspenova-phase-iii-trial-ovarian-cancer<![CDATA[Zentails announced the first dosage of Azenosertib administered in its phase III Aspenova trial to test azenosertib vs chemotherapy in Cyclin E1-positive platinum-resistant ovarian cancer.]]>Wed, 06 May 2026 14:04:18 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/roundup-bayer-acquire-perfuse-therapeutics-madrigal-licensing-agreement-aro-pnpla3https://www.pharmexec.com/view/roundup-bayer-acquire-perfuse-therapeutics-madrigal-licensing-agreement-aro-pnpla3<![CDATA[Madrigal and Bayer strike billion-dollar deals to expand pipelines, with Madrigal licensing a PNPLA3-targeting siRNA for MASH and Bayer acquiring Perfuse Therapeutics to strengthen its ophthalmology portfolio.]]>Wed, 06 May 2026 13:19:40 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/the-past-present-and-future-innovation-of-cardinal-health-3pl-services-and-packaging-solutionshttps://www.pharmexec.com/view/the-past-present-and-future-innovation-of-cardinal-health-3pl-services-and-packaging-solutions<![CDATA[Biopharma manufacturers are navigating growing supply chain complexities, including increased demand for cold chain capacity, the need for sustainable shipping solutions, and the pressure to move products from FDA approval to patients as quickly as possible.]]>Wed, 06 May 2026 13:08:21 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/navigating-sunshine-act-state-transparency-lawshttps://www.pharmexec.com/view/navigating-sunshine-act-state-transparency-laws<![CDATA[]]>Wed, 06 May 2026 12:00:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/from-insight-impact-making-real-world-evidence-actionable-urologyhttps://www.pharmexec.com/view/from-insight-impact-making-real-world-evidence-actionable-urology<![CDATA[Getting from insight to impact requires more than access to information.]]>Wed, 06 May 2026 10:00:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/asembia-asx26-building-value-based-care-models-cell-gene-therapy-will-shrankhttps://www.pharmexec.com/view/asembia-asx26-building-value-based-care-models-cell-gene-therapy-will-shrank<![CDATA[Aradigm Health’s CEO discusses how payers and other entities in the healthcare ecosystem are developing strategies to ensure cell &amp; gene therapy costs don’t prevent patients from accessing them.]]>Wed, 06 May 2026 10:00:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/daily-biontech-reports-2026-first-quarter-resultshttps://www.pharmexec.com/view/daily-biontech-reports-2026-first-quarter-results<![CDATA[In today's Pharmaceutical Executive Daily, Cellenkos announces FDA clearance of its investigational new drug application for CK0802, BioNTech releases its first quarter 2026 financial results, and Peter Harbin argues that biopharma's longstanding deciling-based sales targeting model is overdue for a fundamental rethink. ]]>Tue, 05 May 2026 19:21:22 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/fda-clears-investigational-new-drug-application-phase-ib-iia-trial-ck0802-steroid-refractory-graft-versus-host-diseasehttps://www.pharmexec.com/view/fda-clears-investigational-new-drug-application-phase-ib-iia-trial-ck0802-steroid-refractory-graft-versus-host-disease<![CDATA[FDA clears Cellenkos’ IND for CK0802, enabling a mid-stage trial in steroid-refractory GVHD.]]>Tue, 05 May 2026 18:58:25 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/how-to-overcome-supply-chain-constraints-and-enable-growth-for-cell-gene-therapieshttps://www.pharmexec.com/view/how-to-overcome-supply-chain-constraints-and-enable-growth-for-cell-gene-therapies<![CDATA[Krystal Haynes, Senior Director of Business Development, ICS, at Cencora, outlines the challenges facing cell and gene therapy manufacturers as they attempt to move products from clinical development to commercial availability.]]>Tue, 05 May 2026 15:07:43 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/building-supplier-trust-transparency-and-cross-functional-collaboration-during-a-period-of-volatilityhttps://www.pharmexec.com/view/building-supplier-trust-transparency-and-cross-functional-collaboration-during-a-period-of-volatility<![CDATA[Building effective pharmaceutical supply chain partnerships requires intentional investment in communication, internal alignment, and structured governance to navigate an increasingly volatile industry landscape.]]>Tue, 05 May 2026 15:05:56 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/biontech-releases-first-quarter-results-2026https://www.pharmexec.com/view/biontech-releases-first-quarter-results-2026<![CDATA[BioNTech reports its first quarter finical results, including losses and declining Covid-19 revenue as the company accelerates its oncology investments and restructures its manufacturing footprint. ]]>Tue, 05 May 2026 13:59:13 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/death-decilinghttps://www.pharmexec.com/view/death-deciling<![CDATA[Why biopharma's targeting model is overdue for evolution.]]>Tue, 05 May 2026 10:00:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/asembia-asx26-payers-embracing-value-based-care-models-cell-gene-therapieshttps://www.pharmexec.com/view/asembia-asx26-payers-embracing-value-based-care-models-cell-gene-therapies<![CDATA[Aradigm Health CEO Will Shrank discusses the shift in value-based care models for cell and gene therapies.]]>Tue, 05 May 2026 10:00:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/the-only-ai-simulation-built-for-life-scienceshttps://www.pharmexec.com/view/the-only-ai-simulation-built-for-life-sciences<![CDATA[]]>Mon, 04 May 2026 19:50:17 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/where-precision-meets-pressure-ai-roleplay-built-for-pharma-field-teamshttps://www.pharmexec.com/view/where-precision-meets-pressure-ai-roleplay-built-for-pharma-field-teams<![CDATA[]]>Mon, 04 May 2026 19:49:36 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/ebook-you-only-get-one-shot-at-launch-make-it-count-https://www.pharmexec.com/view/ebook-you-only-get-one-shot-at-launch-make-it-count-<![CDATA[]]>Mon, 04 May 2026 19:40:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/proving-coaching-roi-a-pharma-field-force-transformationhttps://www.pharmexec.com/view/proving-coaching-roi-a-pharma-field-force-transformation<![CDATA[]]>Mon, 04 May 2026 19:39:00 GMTPharmExecusPharmExec Articleshttps://www.pharmexec.com/view/launching-with-confidence-empowering-a-specialized-field-force-for-a-pediatric-formulahttps://www.pharmexec.com/view/launching-with-confidence-empowering-a-specialized-field-force-for-a-pediatric-formula<![CDATA[]]>Mon, 04 May 2026 19:38:00 GMTPharmExecusPharmExec Articles